What Does the Future Hold for Biosimilars in the United States?

Marc O'Connor, Chief Operating Officer of Curant Health, discusses the potential impact of biosimilars on the specialty drug market.

Marc O'Connor, Chief Operating Officer of Curant Health, discusses the potential impact of biosimilars on the specialty drug market.

Related Content:

InterviewsBiosimilarsSpecialty Pharmacy
Connection Between Pharmacists and Prescribers Can Support Mental Health
Meet the Finalists in the 2021 Next-Generation Pharmacist Awards
Expert: MDMA-Assisted Therapy Has Potential Benefits for Women with Hypoactive Sexual Desire Disorder